Look back at pharma news in the week to December 4, 2020

6 December 2020

By Barbara Obstoj-Cardwell. Editor

COVID-19 vaccine news took center stage last week, with Wednesday seeing approval by the UK regulator of Pfizer and BioNTech’s BNT162b2, marking its first approval anywhere in the world. Last Monday Moderna released new data on its COVID-19 vaccine candidate mRNA-1273 and said it was filing for both US and European approval for emergency use. Also, US vaccine developer Novavax updated on the progress of its NVXCoV2373 COVID-19 vaccine program. Elsewhere, Jazz Pharmaceuticals and Spain’s PharmaMar released disappointing Phase III data for their lung cancer drug candidate Zepzelca.

UK asserts its independence with first COVID-19 vaccine nod

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK